Skip to content
Peptide research

Dihexa

Also known as N-Hexanoic-Tyr-Ile-(6)-Aminohexanoic Amide · PNB-0408
Category
Brain & Cognition
Administration routes
Oral
Regulatory status
Not FDA-approved

A synthetic, orally active peptide marketed for memory and cognition, said to amplify HGF signaling and spur new synapse formation. The case rests entirely on rodent studies, with only speculative results in an Alzheimer's mouse model and no human safety data. Its core mechanism, HGF/c-Met, is a known cancer-promoting pathway, and the 2014 paper establishing it was retracted in 2025. It is an unregulated research chemical, not an approved drug in the US.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Note: Dihexa is a peptidomimetic — a modified dipeptide analog of angiotensin IV containing a Tyr-Ile dipeptide core flanked by non-amino-acid modifications (hexanoic acid and aminohexanoic amide). It is included here because of its peptide heritage and common discussion in peptide therapy.

Dihexa (also known as PNB-0408) is a synthetic peptide derived from angiotensin IV, developed at Washington State University by Drs. Joseph Harding and John Wright. It is proposed to boost the activity of hepatocyte growth factor (HGF), a protein that promotes the formation of new connections between brain cells, though the foundational 2014 mechanism paper was retracted in 2025. A 2012 WSU announcement claimed approximately 10 million-fold greater synaptogenic potency than BDNF. This is not an established cognitive benefit, and the associated 2013 study carries an expression of concern. It can be taken orally, crosses the blood-brain barrier, and has shown memory-enhancing effects in multiple animal models of dementia. A related prodrug, fosgonimeton, was investigated in clinical trials, including Phase 2/3 trials for Alzheimer's disease, by Athira Pharma, which subsequently paused its development.

How it works in the body

Proposed to bind HGF and enhance c-Met signaling on neurons; the foundational 2014 mechanism paper was retracted in 2025. The proposed effect is to amplify a signaling cascade that promotes synapse formation, dendritic spine growth, and neural connectivity — processes critical for learning and memory.

Research overview

Dihexa research spans approximately 12 years (2012-2024) and is predominantly preclinical. The compound was designed to activate the HGF/c-Met receptor system in the brain, which drives the formation of new synapses (connections between brain cells) and promotes dendritic growth (the branching structures neurons use to receive signals). Key findings include picomolar-level potency in stimulating new synapse formation in hippocampal cells (the brain's memory center), rescue of drug-induced memory deficits in rats via oral dosing, and restoration of spatial learning in Alzheimer's model mice over 3 months of treatment. However, no human clinical trials of Dihexa itself have been published. Importantly, the foundational 2014 paper establishing the primary mechanism was retracted in April 2025, casting uncertainty on some mechanistic claims. The related pro-drug fosgonimeton reached Phase 2/3 trials for mild-to-moderate Alzheimer's but failed to meet its primary endpoint, though some improvements were observed in biomarkers and certain patient subgroups.

Who researches Dihexa?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching potent synaptogenesis promotion

    One of the primary studied benefits of Dihexa.

Important considerations for

  • Those with Active cancer

    High

    Amplifies HGF/c-Met signaling, which is a known oncogenic pathway in many cancers.

  • Those who are pregnant or breastfeeding

    Absolute

    HGF pathway is critical for embryonic development. Modulation could be teratogenic.

Safety & interactions

Do not use if

  • Active cancer

    High

    Amplifies HGF/c-Met signaling, which is a known oncogenic pathway in many cancers.

General cautions

  • Pregnancy

    Absolute

    HGF pathway is critical for embryonic development. Modulation could be teratogenic.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • HGF/c-Met signaling is a well-established oncogenic pathway

    High

    MET oncology literature / FDA MET-inhibitor approvals

  • Dose-dependent hepatotoxicity reported in rodents

    Theoretical

    No primary source located; figure traces to non-primary web content

  • Aberrant dendritic branching at high doses in animals

    Theoretical

    No primary source located

  • No peer-reviewed human safety trials exist; all safety data from rodents

    High

    Clinical-trial record (fosgonimeton, not dihexa)

  • The 2014 Benoist et al. paper establishing the HGF/c-Met mechanism was retracted in 2025

    High

    Retraction notices PMID 40312093 (2014 paper) and PMID 40312092 (2012 paper)

  • Unregulated products sold online; quality varies

    High

    Regulatory status (no FDA approval)

Interaction summary(6)

Rated by direction with this peptide

  • MET/c-Met inhibitors (crizotinib, capmatinib, tepotinib, cabozantinib)

    CautionModerate

    Direct pharmacodynamic antagonism: dihexa amplifies the very HGF/c-Met signaling these anticancer drugs are designed to block, so co-use could blunt each other and theoretically undermine oncologic therapy. Well-grounded mechanistically; no clinical co-administration data.

    MET-inhibitor mechanism / oncology literature

  • Active or prior malignancy (esp. MET/HGF-driven tumors)

    CautionModerate

    Amplifying a validated oncogenic driver pathway in someone with active or past cancer is a theoretical tumor-promotion risk; no dihexa carcinogenicity data exist to bound it.

    c-Met oncology literature; mechanism

  • Anticholinergic agents (e.g., scopolamine)

    ProtectiveLow

    In rats, oral dihexa fully reversed scopolamine-induced spatial-memory deficits (McCoy 2013, P<0.001), offsetting the anticholinergic cognitive impairment; demonstrated in rodents only, human relevance untested.

    McCoy et al. 2013, PMID 23055539

  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)

    SynergisticTheoretical

    Complementary pro-cognitive mechanisms (neurotrophic vs cholinergic) could in principle be additive, but no combination data exist and the related same-lab HGF/MET-modulating compound fosgonimeton failed its Phase 2/3 AD trial.

    Mechanism-based inference

  • Anti-VEGF / anti-angiogenic therapy (e.g., bevacizumab)

    CautionTheoretical

    MET activation is an established escape/resistance mechanism to anti-angiogenic cancer therapy, so amplifying HGF/MET could theoretically promote resistance; purely mechanistic, no clinical data in this context.

    Oncology literature; mechanism

  • Other neurotrophic / HGF-MET agents (e.g., fosgonimeton, BDNF-pathway nootropics)

    SynergisticTheoretical

    Overlapping neurotrophic signaling could compound both intended effects and unknown risks; no interaction data exist, inference is purely mechanistic.

    Mechanism-based inference

Known risks(8)

  • Oncogenic potential

    High (theoretical)

    HGF/c-Met signaling is a well-established oncogenic pathway. Overexpression of HGF and MET correlates with tumorigenesis, metastasis, and poor prognosis in many cancer types. No carcinogenicity studies have been conducted with dihexa.

  • Hepatotoxicity

    Moderate (observed in animals)

    Dose-dependent hepatotoxicity has been reported in rodent studies, though no primary source for the claim was located. Liver function should be a primary concern for anyone considering this compound.

  • Aberrant neuroplasticity

    Moderate (observed in animals)

    Aberrant dendritic branching patterns have been reported at high doses in animal studies, though no primary source was located. Excessive or disorganized synaptogenesis could theoretically impair rather than improve cognitive function.

  • No human safety data

    High

    No peer-reviewed human safety trials exist for dihexa. All safety data comes from rodent studies with a maximum duration of 3 months. Long-term effects on humans are completely unknown.

  • Retracted foundational research

    Moderate

    The 2014 Benoist et al. paper establishing the HGF/c-Met mechanism was retracted in April 2025, raising questions about the reliability of some mechanistic claims underlying dihexa's proposed benefits.

  • Quality control concerns

    Moderate

    As an unregulated research chemical, dihexa products sold online may vary significantly in purity, potency, and contamination levels. No pharmaceutical-grade manufacturing standards apply.

  • Unknown reproductive/teratogenic effects

    High (data gap)

    No teratogenicity or reproductive toxicity studies have been published, representing a significant safety data gap given the compound's potent growth factor mechanism.

  • Failed pro-drug clinical trial

    Moderate

    The Phase 2/3 LIFT-AD trial of fosgonimeton (dihexa pro-drug) failed to meet its primary endpoint for Alzheimer's disease, raising questions about clinical translatability of preclinical findings.

Drug interactions(5)

  • HGF/c-Met pathway modulators

    High

    Co-administration with other HGF/c-Met activators or inhibitors (e.g., cabozantinib, crizotinib, capmatinib) could produce unpredictable synergistic or antagonistic effects on this oncogenic signaling pathway.

  • Hepatotoxic drugs

    Moderate

    Given dose-dependent hepatotoxicity in rodents, concurrent use with hepatotoxic medications (e.g., acetaminophen at high doses, statins, certain antibiotics) may compound liver injury risk.

  • Anti-cancer therapies

    High

    Dihexa's activation of HGF/c-Met signaling could theoretically counteract anti-cancer therapies, particularly c-Met inhibitors used in oncology. Concurrent use is strongly contraindicated.

  • ACE inhibitors / ARBs

    Low-Moderate (theoretical)

    As an angiotensin IV derivative, dihexa may interact with the renin-angiotensin system. Theoretical interactions with ACE inhibitors or angiotensin receptor blockers have not been studied.

  • Other nootropic peptides

    Interactions with other neurotrophic compounds (e.g., Semax, Selank, cerebrolysin, BPC-157) are completely unstudied. Combining multiple synaptogenic agents could lead to excessive or aberrant neuroplasticity.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
6
Human Studies
0

All published evidence for dihexa itself comes from in vitro cell culture studies and rodent models. No human clinical trials of dihexa have been conducted or published. The pro-drug fosgonimeton has undergone Phase 2/3 human trials for Alzheimer's disease (LIFT-AD study), which did not meet primary endpoints but showed directional biomarker improvements. The foundational 2014 mechanism paper was retracted in April 2025, adding uncertainty to some claims.

Researched for(6)

Rated by confidence in the evidence

  • Potent synaptogenesis promotion

    Low

    Cultured rat neurons grew more dendritic spines at picomolar doses in one 2013 study.

    McCoy et al. 2013, PMID 23055539

  • Rescue of scopolamine-induced cognitive deficits

    Low

    Oral dosing reversed a chemically induced memory deficit in rats, one lab, no human data.

    McCoy et al. 2013, PMID 23055539

  • Cognitive restoration in Alzheimer's mouse model

    Speculative

    A 2021 APP/PS1 mouse study reported improved spatial learning; no human cognitive benefit is established.

    Sun et al. 2021, PMID 34827486; PMC8615599.

  • Blood-brain barrier penetration

    Low

    Radiolabeled tracing showed brain uptake in rats, one lab, with no human confirmation.

    McCoy et al. 2013, PMID 23055539

  • Oral bioavailability

    Low

    Oral dosing was active in rats, but no human oral absorption data exist.

    McCoy et al. 2013, PMID 23055539

  • Exceptional neurotrophic potency

    Speculative

    Picomolar activity was reported in the 2013 study, which carries an expression of concern; the BDNF superiority claim is not established.

    McCoy et al. 2013 (PMID 23055539); retraction PMID 40312093

Benefits(6)

  • Potent synaptogenesis promotion

    In rat hippocampal neuron cultures, dihexa at picomolar concentrations increased dendritic spine density nearly 3-fold (41 vs 15 spines per 50 µm dendrite) (McCoy et al., 2013). Effects were comparable to HGF itself.

  • Rescue of scopolamine-induced cognitive deficits

    Dihexa reversed learning deficits in scopolamine-treated rats in the Morris water maze, effective via oral, intraperitoneal, and intracerebroventricular administration with a clear dose-response relationship (McCoy et al., 2013).

  • Cognitive restoration in Alzheimer's mouse model

    Sun et al. 2021 reported improved spatial learning and PI3K/AKT signaling in APP/PS1 mice after three months; administration route is inconsistently reported.

  • Blood-brain barrier penetration

    Radiolabeled [3H]dihexa infusion studies confirmed the compound crosses the BBB and accumulates in brain tissue, a critical advantage over many peptide-based neurotropic agents.

  • Oral bioavailability

    Oral activity was reported in rats by McCoy et al. 2013. Sun et al. 2021 contains conflicting administration-route descriptions.

  • Exceptional neurotrophic potency

    A 2012 WSU news release about McCoy et al. 2013 claimed approximately 10 million-fold greater synaptogenic potency than BDNF; the study carries a 2021 expression of concern.

Key studies(5)

  1. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents

    Preclinical (in vitro + in vivo rat study; expression of concern issued in 2021)8-10 rats per group; hippocampal neuron cultures5 days in vitro; 8 days behavioral testing

    McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, Harding JW

    Journal of Pharmacology and Experimental Therapeutics

    2013

    Dihexa reversed scopolamine-induced cognitive deficits via oral, intraperitoneal, and ICV routes. Increased hippocampal spine density ~3-fold at picomolar concentrations. Established oral bioavailability and BBB penetration.

  2. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system

    Preclinical (in vitro + in vivo rat study)n=50 per treatment for spine analysis; 8-10 rats per group for behavioral tests5 days neuronal culture; 8 days Morris water maze

    Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW

    Journal of Pharmacology and Experimental Therapeutics

    2014

    Demonstrated dihexa binds HGF with Kd=65 pM, augments c-Met phosphorylation, and induces synaptogenesis dependent on HGF/c-Met activation. RETRACTED April 2025.

  3. Wright JW, Harding JW

    Journal of Alzheimer's Disease

    2015

    Comprehensive review establishing the HGF/c-Met receptor system as a therapeutic target for AD. Summarized dihexa's mechanism as an HGF potentiator promoting dendritic arborization, synaptogenesis, and memory consolidation.

  4. Wright JW, Kawas LH, Harding JW

    Progress in Neurobiology

    2015

    Reviewed the development pipeline from angiotensin IV to dihexa, including pharmacokinetics, BBB penetration data, and potential applications in both Alzheimer's and Parkinson's diseases.

  5. AngIV-analog dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway

    Preclinical (in vivo transgenic mouse study)6-12 mice per group (APP/PS1 and wild-type controls)3 months; administration route inconsistently reported

    Sun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y

    Brain Sciences

    2021

    Dihexa (1.44 and 2.88 mg/kg; route inconsistently reported) restored spatial learning in APP/PS1 Alzheimer's model mice, increased brain angiotensin IV levels, and activated the PI3K/AKT pathway. Independent replication by a Chinese research group.

Regulation & availability

Why researchers look at it

Originally reported to be millions of times more potent than BDNF at promoting new synaptic connections, with animal studies showing reversed memory deficits via simple oral dosing. However, the foundational 2014 paper was retracted in April 2025 and the related pro-drug fosgonimeton failed its Phase 2/3 Alzheimer's trial. Dihexa remains scientifically interesting but carries more unresolved questions than most compounds in this space.

FDA status
Not FDA-approved for any indication. Dihexa has no IND (Investigational New Drug) status on its own. Its pro-drug fosgonimeton (formerly NDX-1017) has FDA IND status and has undergone Phase 1, Phase 2, and Phase 2/3 clinical trials for Alzheimer's disease and Parkinson's disease dementia under Athira Pharma. The Phase 2/3 LIFT-AD trial did not meet its primary endpoint.
WADA status
Not explicitly listed on the WADA Prohibited List by name. However, dihexa could potentially fall under WADA's S2 category (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) as a growth factor mimetic/potentiator, or under S0 (Non-Approved Substances) as it is not approved for human therapeutic use by any regulatory authority. Athletes should assume it is prohibited and consult their national anti-doping organization before any use.
Prescribability
Dihexa is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use. FDA plans to ask its advisory committee about adding it before the end of February 2027. Fosgonimeton underwent human trials, but Athira paused further development and its open-label extension concluded.
Availability
Dihexa is not FDA-approved for human therapeutic use. FDA retains safety concerns for dihexa acetate after withdrawal of its compounding nomination. Fosgonimeton underwent clinical development under Athira Pharma; further development was paused.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(9)

  1. 2012
    Initial publication of dihexa as a procognitive agent by Harding and Wright at Washington State University (McCoy et al., published October 2012, PMID 23055539).
  2. 2014
    Benoist et al. published the HGF/c-Met mechanism paper establishing dihexa's molecular target (PMID 25187433). M3 Biotechnology (founded 2011) begins commercializing dihexa.
  3. 2015
    Two major review articles published by Wright and Harding in Journal of Alzheimer's Disease and Progress in Neurobiology, establishing the therapeutic rationale.
  4. 2016-2018
    M3 Biotechnology (later renamed Athira Pharma) developed fosgonimeton (NDX-1017), a phosphate pro-drug of dihexa, for clinical advancement. Phase 1 trials initiated.
  5. 2021
    Sun et al. published independent replication of dihexa's cognitive benefits in APP/PS1 mice (PMID 34827486). Athira Pharma advanced fosgonimeton to Phase 2/3 (LIFT-AD trial).
  6. 2023-2024
    LIFT-AD Phase 2/3 trial completed enrollment and reported topline results. Primary endpoint not met, though directional biomarker improvements observed in subgroups.
  7. April 2025
    Benoist et al. 2014 paper (PMID 25187433) retracted, casting uncertainty on the foundational HGF/c-Met mechanism data for dihexa.
  8. February 2026
    FDA issued guidance document requiring heightened scrutiny for BBB-penetrating peptides exceeding 50% penetration rates, applicable to dihexa in institutional research settings.
  9. 2026 (current)
    Dihexa remains a preclinical research compound with no FDA-approved indication. FDA reports no human exposure data for dihexa acetate by any route. Athira paused fosgonimeton development, and its open-label extension concluded in 2024.

Sources & FAQs

Research sources(10)

Frequently asked questions(6)

What is dihexa and how does it work?

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide derived from angiotensin IV. Its proposed mechanism involves HGF binding and enhanced c-Met signaling, but the foundational 2014 evidence was retracted in 2025. That signaling is proposed to promote the formation of new synaptic connections (synaptogenesis), dendritic branching, and spine growth in neurons, processes associated with learning and memory.

Is the '10 million times more potent than BDNF' claim accurate?

This claim comes from in vitro neurotrophic activity assays comparing effective concentrations. Dihexa operates at picomolar concentrations while BDNF works at nanomolar concentrations for similar synaptogenic effects. However, this comparison is between different molecular mechanisms (HGF/c-Met vs TrkB signaling) and does not mean dihexa is '10 million times better' for cognition. The numerical claim appeared in a 2012 WSU news release about the McCoy study, published in 2013. That study carries a 2021 expression of concern; the separate 2014 mechanism paper was retracted in April 2025.

Has dihexa been tested in humans?

No. All published research on dihexa itself is preclinical (cell culture and animal studies). However, fosgonimeton — a phosphate pro-drug that converts to dihexa in the body — has been tested in Phase 2/3 human clinical trials for Alzheimer's disease (the LIFT-AD trial), though it failed to meet its primary endpoint.

What are the main safety concerns with dihexa?

The primary concerns are: (1) HGF/c-Met activation is a known driver of tumor growth, invasion, and metastasis in many cancers — no carcinogenicity studies have been conducted; (2) dose-dependent hepatotoxicity observed at high doses in rodent studies; (3) aberrant dendritic branching at high doses in animal studies; (4) no long-term safety data beyond 3-month animal studies; (5) no teratogenicity or reproductive toxicity data exists.

What is the difference between dihexa and fosgonimeton?

Fosgonimeton is a phosphate pro-drug of dihexa, meaning it is converted into dihexa in the body. It was developed for improved pharmaceutical properties and was investigated in clinical trials by Athira Pharma (formerly M3 Biotechnology), which subsequently paused its development.

Is dihexa legal?

Dihexa occupies a regulatory gray area. It is not a controlled substance but is also not approved for human use. Selling it for human consumption would violate FDA regulations. Its legal status varies by jurisdiction.